Eli Lilly says its experimental “triple-G” drug, retatrutide, outperformed Novo Nordisk’s blockbuster Ozempic in a head-to-head diabetes trial — meaning sharper blood sugar control and greater weight loss for people with type 2 diabetes. The company shared the data as part of its ongoing late-stage trial programme, and it’s already being read as a shot across Novo’s bow. For India, where diabetes numbers keep climbing every year, this is a story worth watching closely.
Key Takeaways
- Lilly’s triple-G drug, retatrutide, reportedly beat semaglutide (Ozempic) on both blood sugar reduction and weight loss in a recent diabetes study.
- Retatrutide works on three gut hormone pathways at once — GLP-1, GIP, and glucagon — which is why it’s nicknamed the “triple-G” drug.
- The drug is still in late-stage trials and has not been approved anywhere, including India, so it isn’t available to patients yet.
- India’s own diabetes and obesity burden means any genuinely better treatment option will eventually matter here — but affordability and access will decide how much.
What Exactly Did Lilly Say About the Triple-G Drug?
Lilly’s announcement, first reported in detail by STAT News, said that retatrutide produced bigger improvements in HbA1c (the standard marker doctors use to track average blood sugar over three months) compared with semaglutide, the active ingredient in Ozempic. Patients on retatrutide also lost more body weight over the course of the study.
Lilly hasn’t published the full peer-reviewed dataset yet — that typically follows months later at a medical conference or in a journal. So for now, treat the “beat Ozempic” claim as a topline company readout, not an independently verified result. That’s a normal part of how drug trials get reported; the fuller picture usually arrives in stages.
Why Is Retatrutide Called a “Triple-G” Drug?
Most diabetes injections you’ve heard of — Ozempic, Wegovy, Rybelsus — work on one receptor: GLP-1. Lilly’s Mounjaro and Zepbound (tirzepatide) added a second: GIP. Retatrutide goes one step further and activates a third pathway, the glucagon receptor, alongside GLP-1 and GIP. That’s the “triple-G” in triple-G drug — three hormone receptors, one molecule.
The theory is straightforward: each of these hormones nudges the body differently — slowing digestion, improving insulin response, or nudging the liver to burn stored fat. Hit all three together, and the effect on blood sugar and weight could be stronger than hitting just one. You can read more about how the molecule is designed on its Wikipedia entry on retatrutide, which lays out the mechanism in plain terms.
How Does the Triple-G Drug Compare With Ozempic and Mounjaro?
Here’s a simple side-by-side based on what’s publicly known so far. Keep in mind retatrutide’s numbers come from earlier mid-stage data and Lilly’s own trial reporting, not a final approved label.
| Drug | Receptors targeted | Status | Maker |
| Ozempic (semaglutide) | GLP-1 only | Approved, widely prescribed | Novo Nordisk |
| Mounjaro (tirzepatide) | GLP-1 + GIP | Approved in several markets, including India | Eli Lilly |
| Retatrutide (“triple-G drug”) | GLP-1 + GIP + glucagon | Late-stage trials, not yet approved | Eli Lilly |
In an earlier Phase 2 study published in the New England Journal of Medicine in 2023, people on the highest dose of retatrutide lost roughly a quarter of their body weight over a year — numbers that turned heads across the diabetes and obesity research world. The new diabetes trial Lilly is now talking about builds on that early promise.
What Does This Mean for Diabetes Care in India?
India already carries one of the world’s largest diabetes burdens — estimates from the ICMR-INDIAB study put the number of adults living with diabetes well into the tens of millions, with many more in the prediabetes stage. A chunk of that is tied to rising obesity, especially in cities, which is exactly the territory these new-generation drugs are built for.
Here’s the honest part, though: neither Ozempic nor Mounjaro is cheap or universally available in India yet, and retatrutide is years away from any Indian approval, let alone affordable pricing. So this isn’t a “run to your chemist” story. It’s a “watch this space” story — useful context for anyone managing diabetes risk with their doctor right now, rather than something to act on today.
What I’d tell a patient in my own family: don’t wait for a future pill or injection to fix what a few basic checkups can catch early. An annual fasting blood sugar and HbA1c test after age 30 — sooner if there’s a family history — still catches most trouble well before any drug, old or new, becomes necessary.
When Could the Triple-G Drug Reach Indian Patients?
- Lilly needs to complete and publish full Phase 3 results for retatrutide in diabetes, not just topline numbers.
- It then needs regulatory approval in a major market like the US or EU, which usually takes at least a year or two after submission.
- Only after that does an India launch via the Central Drugs Standard Control Organisation (CDSCO) typically follow — often with a gap of one to three years behind Western launches, going by how Mounjaro reached India.
- Pricing and insurance coverage decisions come last, and those shape how many people can actually use it here.
Realistically, we’re looking at the back half of this decade before retatrutide, if approved, becomes something an Indian endocrinologist can actually prescribe.
FAQ
What is Lilly’s triple-G drug?
It’s retatrutide, an injectable medicine from Eli Lilly that targets three hormone receptors — GLP-1, GIP, and glucagon — to improve blood sugar control and support weight loss in people with type 2 diabetes or obesity.
Did the triple-G drug really beat Ozempic?
Eli Lilly reported that retatrutide outperformed semaglutide (Ozempic) on blood sugar and weight measures in a company trial readout. Full peer-reviewed data hasn’t been published yet, so independent experts haven’t fully verified the claim.
Is retatrutide available in India?
No. Retatrutide is still in clinical trials and hasn’t been approved by any major regulator, including India’s CDSCO. It isn’t available through pharmacies or hospitals yet.
Is retatrutide the same as Mounjaro?
No. Mounjaro (tirzepatide) targets two hormone receptors — GLP-1 and GIP. Retatrutide adds a third, the glucagon receptor, which is why it’s called the triple-G drug.
Should Indian diabetes patients switch medicines because of this news?
No. This is early trial news about a drug that isn’t approved anywhere yet. Anyone managing diabetes should keep following their doctor’s current plan and regular checkup schedule.
The bottom line: Lilly’s triple-G drug looks promising on paper, and if the fuller data holds up, it could reshape how diabetes and obesity get treated worldwide in the next few years. For now, in India, the smarter move is sticking to proven basics — regular screening, steady lifestyle changes, and medicines your own doctor already trusts.